| P50 | author | Jian Wu | Q82564702 |
| P2093 | author name string | Yang Li | |
| | Junbo Ge | |
| | Yunzeng Zou | |
| | Shijun Wang | |
| | Hui Gong | |
| | Jie Yuan | |
| | Yong Ye | |
| | Guoliang Jiang | |
| | Weijing Zhang | |
| | Xingxu Wang | |
| | Peipei Yin | |
| | Zhiwen Ding | |
| | Jingmin Zhou | |
| P2860 | cites work | Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury | Q28252995 |
| | 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q29620107 |
| | Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma | Q29622918 |
| | Comparing angiotensin II receptor blockers on benefits beyond blood pressure | Q30360678 |
| | Modeling the effects of β1-adrenergic receptor blockers and polymorphisms on cardiac myocyte Ca2+ handling. | Q30371695 |
| | Autophagy in hypertensive heart disease | Q33726330 |
| | Autophagy and oxidative stress in cardiovascular diseases | Q34506174 |
| | ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the | Q34640762 |
| | The intracellular renin-angiotensin system in the heart | Q34960931 |
| | Mechanical stress triggers cardiomyocyte autophagy through angiotensin II type 1 receptor-mediated p38MAP kinase independently of angiotensin II. | Q35107771 |
| | Working outside the system: an update on the unconventional behavior of the renin-angiotensin system components | Q36099604 |
| | Induction of cardiac fibrosis by β-blocker in G protein-independent and G protein-coupled receptor kinase 5/β-arrestin2-dependent Signaling pathways. | Q36318886 |
| | Stop and go: anti-proliferative and mitogenic functions of the transcription factor C/EBPbeta | Q36474712 |
| | Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure : a clinical review | Q36666482 |
| | ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium | Q37145440 |
| | The electrophysiological effects of qiliqiangxin on cardiac ventricular myocytes of rats | Q37286000 |
| | Apoptosis in pressure overload-induced heart hypertrophy in the rat. | Q37356640 |
| | Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects | Q37678849 |
| | Direct renin inhibitors as antihypertensive agents. | Q37755936 |
| | The diagnosis and management of chronic heart failure: review following the publication of the NICE guidelines. | Q37836177 |
| | The role of cell signalling in the crosstalk between autophagy and apoptosis | Q38168965 |
| | The regulation of β-adrenergic receptor-mediated PKA activation by substrate stiffness via microtubule dynamics in human MSCs | Q38980205 |
| | Anti-beta1-adrenergic receptor autoantibodies are potent stimulators of the ERK1/2 pathway in cardiac cells | Q40107520 |
| | Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure | Q41196451 |
| | Essential role for UVRAG in autophagy and maintenance of cardiac function. | Q41924071 |
| | Myocyte apoptosis occurs early during the development of pressure-overload hypertrophy in infant myocardium | Q42194690 |
| | C/EBPβ controls exercise-induced cardiac growth and protects against pathological cardiac remodeling | Q42591580 |
| | Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice | Q42859674 |
| | Mechanical stress-evoked but angiotensin II-independent activation of angiotensin II type 1 receptor induces cardiac hypertrophy through calcineurin pathway. | Q43004529 |
| | Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study | Q43810164 |
| | Qiliqiangxin regulates the balance between tumor necrosis factor-alpha and interleukin-10 and improves cardiac function in rats with myocardial infarction | Q44478235 |
| | Convergence in findings from randomized trials and elaborately analysed observational data on mortality reduction with carvedilol in heart failure in comparison with metoprolol | Q44581731 |
| | Qiliqiangxin improves cardiac function in spontaneously hypertensive rats through the inhibition of cardiac chymase | Q44643319 |
| | The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. | Q44694136 |
| | Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. | Q44898088 |
| | Effects of angiotensin-converting enzyme inhibitor, captopril, on bone of mice with streptozotocin-induced type 1 diabetes. | Q45859011 |
| | Ryanodine receptor type 2 is required for the development of pressure overload-induced cardiac hypertrophy. | Q46010252 |
| | Life and death partners: apoptosis, autophagy and the cross-talk between them | Q46072576 |
| | Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 |
| | A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure | Q48228910 |
| | Comparison of alprazolam versus captopril in high blood pressure: a randomized controlled trial. | Q50645690 |
| | Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice. | Q54550660 |
| | Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial | Q57396324 |
| | p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload | Q57396501 |
| | [Guidelines for the diagnosis and management of chronic heart failure] | Q80874938 |
| | Promising small molecule for heart failure targeting adrenal catecholamine release and β-adrenergic receptor signaling in the heart | Q87618243 |
| | Chronic treatment with qiliqiangxin ameliorates aortic endothelial cell dysfunction in diabetic rats | Q88034124 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 628-639 | |
| P577 | publication date | 2015-06-01 | |
| P1433 | published in | Journal of Cardiovascular Pharmacology | Q2125808 |
| P1476 | title | Combination Treatment With Antihypertensive Agents Enhances the Effect of Qiliqiangxin on Chronic Pressure Overload-induced Cardiac Hypertrophy and Remodeling in Male Mice | |
| P478 | volume | 65 | |